Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer announced positive results from the Phase 3 trial of its investigational pentavalent meningococcal vaccine, MenABCWY, demonstrating safety and immunogenicity non-inferior to existing licensed vaccines. The trial met all primary and secondary endpoints, providing broad serogroup coverage. Pfizer plans to submit a Biologics License Application to the FDA in Q4 2022, which, if approved, could simplify the vaccination schedule for approximately 52 million adolescents in the U.S. and improve meningococcal disease protection.
Pfizer Inc. (NYSE: PFE) will hold a conference call on September 21, 2022, at 4:30 p.m. EDT, focusing on oral GLP-1 data from the European Association for the Study of Diabetes 2022. Investors can join the webcast via Pfizer's investor site, and are encouraged to register in advance. Participants can also listen by calling 800-456-4352 (U.S. and Canada) or 785-424-1086 (international), with passcode “70409”. A transcript and replay will be available for 90 days on the investor site.
Pfizer Inc. (NYSE: PFE) has initiated a pivotal Phase 3 clinical trial for its mRNA-based influenza vaccine, enrolling approximately 25,000 healthy adults in the U.S. This study aims to evaluate the vaccine's efficacy, safety, and immunogenicity. With influenza annually causing up to 710,000 hospitalizations and 52,000 deaths in the U.S., the need for improved vaccines is critical. mRNA technology may allow better strain matches and more rapid production, potentially enhancing vaccine effectiveness.
Pfizer (NYSE: PFE) has expanded its collaboration with Strata Oncology for the Strata PATH trial, which will now include treatment for new micrometastatic patient cohorts. Pfizer will provide several FDA-approved cancer therapies, including Braftovi® and Lorbrena®, for patients with early-stage cancer showing micrometastatic disease. The trial aims to evaluate the safety and efficacy of these therapies on a broader patient population. This initiative underscores the potential of precision oncology in advancing cancer treatment.
Pfizer and BioNTech have received a conditional marketing authorization recommendation from the EMA's CHMP for their bivalent Omicron BA.4/BA.5 COVID-19 vaccine for individuals 12 years and older. The vaccine combines components targeting both the original SARS-CoV-2 and Omicron subvariants, designed to elicit a strong immune response. If approved by the European Commission, distribution will commence immediately to support EU vaccination efforts this fall. Previous data showed a superior immune response against Omicron subvariants compared to the existing vaccine.
Pfizer Inc. (NYSE: PFE) announced that the FDA accepted the New Drug Application (NDA) for ritlecitinib for treating alopecia areata in adults and adolescents. The FDA decision is expected in Q2 2023, while the EMA's Marketing Authorization Application (MAA) decision is anticipated in Q4 2023. Ritlecitinib is a new oral treatment aimed at regrowing hair, showing statistically significant results in clinical trials. Alopecia areata affects approximately 6.8 million people in the U.S. and around 147 million globally.
Pfizer Inc. (NYSE:PFE) announced that its investigational GBS vaccine, GBS6, has received Breakthrough Therapy Designation from the FDA. This designation aims to expedite the development of GBS6, aimed at preventing invasive Group B Streptococcus disease in newborns. The decision is based on interim analysis from an ongoing Phase 2 trial in pregnant women. If approved, GBS6 could significantly reduce neonatal diseases, addressing a critical public health need. GBS6 targets the six main GBS serotypes, accounting for 98% of global cases.
Summary not available.
Summary not available.
Pfizer Inc. (NYSE: PFE) will present at two upcoming healthcare conferences. Chief Scientific Officer Mikael Dolsten will speak at Citi's 17th Annual BioPharma Conference on September 7, 2022, at 10:30 a.m. EDT, while Chief Financial Officer David Denton will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 9:10 a.m. EDT. Investors can access the live webcasts and subsequent replays on Pfizer's investor relations website. Forward-looking statements discussed may involve risks that could materially impact actual results.